文献速递妇科产科

非DES时代宫颈与阴道透明细胞癌63例回顾性研究

Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-DES era.
PubMed 文献 · Gynecol Oncol · 2026-02-05

该回顾性横断面研究纳入2000–2024年诊断的63例宫颈和阴道透明细胞癌患者(宫颈51例、阴道12例),采用FIGO 2018分期和Kaplan-Meier/Cox模型分析生存与复发。宫颈透明细胞癌复发21例(41.2%),中位OS为12.96年;阴道透明细胞癌复发10例(83.3%),中位OS为3.26年。宫颈透明细胞癌预后优于阴道透明细胞癌,分期和淋巴结转移是宫颈透明细胞癌的生存预测因素。

要点

  • 宫颈透明细胞癌复发率41.2%,中位OS 12.96年,早期预后较好。
  • 阴道透明细胞癌复发率83.3%,中位OS 3.26年,预后较宫颈差。
  • 淋巴结转移与宫颈透明细胞癌更差的OS和RFS相关。

核心结论

  • 宫颈透明细胞癌患者预后优于阴道透明细胞癌患者。
  • 分期和淋巴结转移是宫颈透明细胞癌生存结局的预测因素。

研究设计与样本

  • 回顾性横断面研究,纳入2000–2024年诊断的63例宫颈和阴道透明细胞癌患者(宫颈51例、阴道12例)。
  • 宫颈癌采用FIGO 2018分期,分为早期(IA1-IB2、IIA1)、局部晚期(IB3、IIA2-IVA)和晚期(IVB)。
  • 采用Kaplan-Meier法估计OS和RFS,并用Cox比例风险回归建模。

主要发现

  • 宫颈透明细胞癌组复发21例(41.2%),中位OS为12.96年(95% CI 8.83, 15.5)。
  • 宫颈透明细胞癌中,早期疾病与更高的OS(P=0.01)和RFS(P=0.00049)相关。
  • 宫颈透明细胞癌中,淋巴结转移与较差的OS(P=0.0001)和RFS(P=0.0113)相关。
  • 阴道透明细胞癌组复发10例(83.3%),中位OS为3.26年(95% CI 0.77, 6.75)。
  • 与宫颈透明细胞癌相比,阴道透明细胞癌预后更差,OS(P=0.0009)和RFS(P=0.0029)更低。

临床怎么用

  • 应重视宫颈透明细胞癌的分期和淋巴结转移状态以评估预后。
  • 阴道透明细胞癌预后较差,需更密切的随访和个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the clinical characteristics and oncologic outcomes of cervical and vaginal clear cell carcinoma (cCCC, vCCC) in the post-DES era. METHODS: This is a retrospective cross-sectional study of patients diagnosed with cCCC and vCCC between 2000 and 2024. Cervical cancer was staged using the International Federation of Gynecology and Obstetrics (FIGO) 2018 system and categorized as early stage (IA1-IB2, IIA1), locally advanced (IB3, IIA2-IVA) and advanced (IVB). Overall survival (OS) and recurrence-free survival (RFS) were estimated with the Kaplan-Meier product-limit estimator and modeled via Cox proportional hazards regression. RESULTS: A total of 63 patients were included: 51 cervical and 12 vaginal. Among cCCC, recurrence occurred in 21 patients (41.2%), with a median OS of 12.96 years (95% CI 8.83, 15.5). Early-stage disease was associated with a higher OS (p-value = 0.01) and RFS (p-value = 0.00049) compared to locally advanced and advanced disease. Lymph node metastasis was associated with poor OS (p-value = 0.0001) and RFS (p-value = 0.0113). In the vCCC group, recurrence was identified in 10 patients (83.3%), with a median OS of 3.26 years (95% CI 0.77, 6.75). Compared to cCCC, vCCC had worse prognosis with lower OS (p-value = 0.0009) and RFS (p-value = 0.0029). CONCLUSION: Patients with cCCC have more favorable outcomes than those with vCCC, with stage and lymph node metastasis serving as predictors of survival outcomes in cCCC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Saab R, Brazan A, Chisholm GB, et al. Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-DES era. Gynecol Oncol. 2026. PMID: 41650791. doi:10.1016/j.ygyno.2026.01.773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。